Chemomab Therapeutics price target raised to $7 from $4 at Maxim

Maxim raised the firm’s price target on Chemomab Therapeutics (CMMB) to $7 from $4 and keeps a Buy rating on the shares. The firm cites the company’s favorable results from the End-of-Phase 2 meeting with FDA for CM-101 in primary sclerosing cholangitis, the analyst tells investors in a research note. The “robust” outcome avoids the need for biopsy and confirmatory studies, significantly streamlining the path to approval in line with previously expected timelines, Maxim adds.